Randomized phase II study of TJ-17 and TJ-114 in patients with lower limb lymphedema after lymphadenectomy for gynecologic malignancy

Randomized phase II study of TJ-17 and TJ-114 in patients with lower limb lymphedema after lymphadenectomy for gynecologic malignancy - Randomized phase II study of TJ-17 and TJ-114 in patients with lower limb lymphedema after lymphadenectomy for gynecologic malignancy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033605

Enrollment

Registered

2018-10-01

Start date

2018-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary lower limb lymphedema

Interventions

TJ-17 8 weeks TJ-114 8 weeks control

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients with lower limb lymphedema after lymphadenectomy for gynecologic malignancy

Exclusion criteria

Exclusion criteria: women were excluded if they 1) were allergy for TJ-17 or TJ-114 2) had other medical severe conditions (i.e., congestive heart failure, chronic/acute renal disease,nephrotic syndrome, nephrosis, liver failure, or severe psychatric disease) 3) were unable to eat 4) were diagnosed as primary lymphedema 5) were suffered from lower limb vein thrombosis 6) were not suitable for participation

Design outcomes

Primary

Measure	Time frame
limb circumference	—

Countries

Japan

Contacts

Public ContactNobuhisa Yoshikawa

Nagoya University Hospital Obstetrics and Gynecology

n-yoshikawa@med.nagoya-u.ac.jp052-744-2261

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026